Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BJHL Biotech, Inc. 〉JHL1152 Ipilimumab Biosimilar

JHL1152 Ipilimumab Biosimilar

JHL1152 Ipilimumab Biosimilar

A cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody

Request for Collaboration
Overview
JHL1152 is a proposed biosimilar to ipilimumab, a cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody.
Application
Late-Stage Melanoma
People who like this also like
  • Clinical & Regulatory ExpertiseClinical & Regulatory Expertise
  • The Most Professional AccreditationThe Most Professional Accreditation
  • PHDC-02PHDC-02
  • Multi-day Transdermal Drug Delivery (MTDD)Multi-day Transdermal Drug Delivery (MTDD)
  • Zwitterionic interface processing technologyZwitterionic interface processing technology
  • JHL1266 Denosumab BiosimilarJHL1266 Denosumab Biosimilar
  • BioImage AnalyzerBioImage Analyzer
  • New combination for treating SialorrheaNew combination for treating Sialorrhea
  • Pegylation PlatformPegylation Platform
  • PHN015 (Hemorrhage stroke)PHN015 (Hemorrhage stroke)